Patrick J Heron bought $73k of MIRM
director at Mirum Pharmaceuticals, Inc.. 1,602 shares at an average of $45.40, traded Mar 4, 2025, filed Mar 6, 2025.
Score components
- +15RoleDirector
- +8Trade size$73k at market
- -5Relative to holdingsUnder 1% of holdings (1.0%)
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-007260, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 4, 2025 | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +1,279 | $45.55 | $58k | 163,587 | Mar 6, 2025 |
| Mar 4, 2025 | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +56 | $45.96 | $2,574 | 163,643 | Mar 6, 2025 |
| Mar 5, 2025 | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +267 | $44.55 | $12k | 163,910 | Mar 6, 2025 |
Related signals
Other insiders at Mirum Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 52Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $978k 9,943 shares | -18% | |
| 38Weak | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $66k 658 shares | -52% | |
| 35Weak | Mirum Pharmaceuticals, Inc. | Christopher Peetz CHIEF EXECUTIVE OFFICER | $3.0M 30,000 shares | -13% | |
| 41Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $728k 9,578 shares | -19% | |
| 53Moderate | Mirum Pharmaceuticals, Inc. | Laura Brege director | $1.3M 17,000 shares | -52% | |
| 28Weak | Mirum Pharmaceuticals, Inc. | Christopher Peetz CHIEF EXECUTIVE OFFICER | $2.5M 40,000 shares | -22% | |
| 27Weak | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $580k 10,000 shares | -80% | |
| 28Weak | Mirum Pharmaceuticals, Inc. | Christopher Peetz CHIEF EXECUTIVE OFFICER | $2.2M 40,000 shares | -22% | |
| 0Weak | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $51k 1,041 shares | -30% | |
| 54Moderate | Mirum Pharmaceuticals, Inc. | William Fairey director | $155k 3,203 shares | -56% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.